Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25197574 | 1.00 | TYR (0.47) | TYROPRM1OPRD1NPC1RAB9A | |
| SCHEMBL25471854 | 0.82 | PPARG (0.52) | — | |
| SCHEMBL25471960 | 0.82 | PPARG (0.52) | OPRM1OPRD1 | |
| SCHEMBL17919045 | 0.81 | PPARG (0.49) | — | |
| SCHEMBL11792982 | 0.78 | SLC7A5 (0.68) | — | |
| SCHEMBL25471957 | 0.78 | OPRD1 (0.42) | OPRM1OPRD1 | |
| SCHEMBL25471849 | 0.78 | OPRD1 (0.42) | OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL11454672 | 0.77 | SLC7A5 (0.66) | — | |
| SCHEMBL31121645 | 0.77 | DYRK1A (0.56) | — | |
| SCHEMBL7260035 | 0.77 | TYR (0.50) | TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2024-06-27 | — | — | US | claimed |
| EP-4305049-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2024-01-17 | — | — | EP | claimed |
| WO-2022190100-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2022-09-15 | — | — | WO | claimed |
| US-20250082595-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON’S DISEASE | NEURODERM LTD (IL) | 2025-03-13 | — | — | US | disclosed |
| US-20240315997-A1 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | NEURODERM, LTD. (IL) | 2024-09-26 | — | — | US | disclosed |
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2024-06-27 | — | — | US | disclosed |
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2024-06-27 | — | — | US | disclosed |
| EP-4305049-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2024-01-17 | — | — | EP | disclosed |
| US-11844754-B2 | Methods for treatment of Parkinson's disease | NEURODERM, LTD. (IL) | 2023-12-19 | — | — | US | disclosed |
| WO-2023126945-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-07-06 | — | — | WO | disclosed |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
| WO-2022190100-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844754-B2 | Methods for treatment of Parkinson's disease | DDC, DDT, SLC6A3 | TYR 472/4885OPRM1 285/4885OPRD1 420/4885 |
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | COMT, TH, DDT | TYR 5/4885OPRM1 1686/4885OPRD1 1037/4885 |
| US-20240315997-A1 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | DDC, DDT, COMT | TYR 197/4885OPRM1 274/4885OPRD1 352/4885 |
| US-20250082595-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON’S DISEASE | DDC, COMT, DDT | TYR 72/4885OPRM1 251/4885OPRD1 318/4885 |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | DDC, DDT, COMT | TYR 460/4885OPRM1 276/4885OPRD1 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.